Core Laboratories (NYSE:CLB) Misses Q2 CY2026 Sales Expectations
Core Laboratories (NYSE:CLB) reported Q2 CY2026 revenue of $124.6 million, down 4.3% year on year, missing analysts’ sales expectations. Non-GAAP profit was $0.11 per share, 26.9% above consensus. Adjusted EBITDA margin was 11.1% and free cash flow was $3.12 million (2.5% margin). The stock fell 4.2% to $9.45 after the release.
How this was made
The 30-second read
Why it matters
The key new decision input is the Q2 CY2026 revenue miss versus expectations, alongside an EPS beat and adjusted EBITDA beat, plus weaker free cash flow and margin contraction details.
Market read
A revenue shortfall with mixed profitability and cash flow metrics can shift valuation expectations and near-term positioning for CLB.
What to watch
The article notes free cash flow was low ($3.12M, 2.5% margin) and down YoY; traders may want to separate near-term revenue weakness from longer-cycle cash durability and expense trends.
Background
Core Laboratories is an oilfield services firm analyzing rock and fluid samples to help optimize oil and gas production and recovery.
Ticker impact
Core Laboratories reported Q2 CY2026 revenue of $124.6M, down 4.3% YoY, missing Wall Street expectations while EPS beat.
Choppy to downside-biased reaction risk, consistent with the stock trading down 4.2% to $9.45 immediately after the report.
The article provides the revenue miss magnitude, EPS beat, and the immediate post-report stock move, which together frame a mixed but net-negative fundamental read-through.
Market effects
Signals continued softness in oilfield services demand or activity levels, with cash generation and margin efficiency highlighted as watch items.
None explicitly stated.
None explicitly stated.
Counterpoint
EPS and adjusted EBITDA beat could indicate cost discipline and resilience, so the revenue miss may be temporary rather than a structural deterioration.
Key entities
- companyCore Laboratories
Oilfield services company reporting Q2 CY2026 results with revenue down 4.3% YoY and EPS beat.
